About: Hemorrhagic stroke and anticoagulation in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hemorrhagic stroke and anticoagulation in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hemorrhagic stroke and anticoagulation in COVID-19
Creator	Horwitz, Leora Berger, Jeffrey Dogra, Siddhant Galetta, Steven Jain, Rajan Lewis, Ariane Melmed, Kara Bilaloglu, Seda Cao, Meng Hochman, Katherine Hochman, Sarah Org, Leora Steven, : Zagzag, David
Source	Elsevier; Medline; PMC
abstract	Abstract Background and Purpose : Patients with the Coronavirus Disease of 2019 (COVID-19) are at increased risk for thrombotic events and mortality. Various anticoagulation regimens are now being considered for these patients. Anticoagulation is known to increase the risk for adverse bleeding events, of which intracranial hemorrhage (ICH) is one of the most feared. We present a retrospective study of 33 patients positive for COVID-19 with neuroimaging-documented ICH and examine anticoagulation use in this population. Methods : Patients over the age of 18 with confirmed COVID-19 and radiographic evidence of ICH were included in this study. Evidence of hemorrhage was confirmed and categorized by a fellowship trained neuroradiologist. Electronic health records were analyzed for patient information including demographic data, medical history, hospital course, laboratory values, and medications. Results : We identified 33 COVID-19 positive patients with ICH, mean age 61.6 years (range 37 to 83 years), 21.2% of whom were female. Parenchymal hemorrhages with mass effect and herniation occurred in 5 (15.2%) patients, with a 100% mortality rate. Of the remaining 28 patients with ICH, 7 (25%) had punctate hemorrhages, 17 (60.7%) had small- moderate size hemorrhages, and 4 (14.3%) had a large single site of hemorrhage without evidence of herniation. Almost all patients received either therapeutic dose anticoagulation (in 22 [66.7%] patients) or prophylactic dose (in 3 [9.1] patients) prior to ICH discovery. Conclusions : Anticoagulation therapy may be considered in patients with COVID-19 though the risk of ICH should be taken into account when developing a treatment regimen.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1016/j.jstrokecerebrovasdis.2020.104984
bibo:pmid	32689588
has license	els-covid
sha1sum (hex)	7910866f717588c2d63ddfcb11e305e8e2006b44
schema:url	https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104984
resource representing a document's title	Hemorrhagic stroke and anticoagulation in COVID-19
has PubMed Central identifier	PMC7245254
has PubMed identifier	32689588
schema:publication	J Stroke Cerebrovasc Dis
resource representing a document's body	covid:7910866f717588c2d63ddfcb11e305e8e2006b44#body_text
is schema:about of	named entity 'thrombotic' named entity 'positive' named entity 'mortality' named entity 'patients' named entity 'THESE' named entity 'COVID-19' named entity 'PATIENTS' named entity 'MORTALITY' named entity 'DOCUMENTED' named entity 'VARIOUS' covid:arg/7910866f717588c2d63ddfcb11e305e8e2006b44 named entity 'COVID-19' named entity 'risk' named entity 'neuroimaging' named entity 'thrombotic events' named entity 'anticoagulation' named entity 'Coronavirus' named entity 'risk' named entity 'hemorrhages' named entity 'medical history' named entity 'tumor resection' named entity 'empiric' named entity 'parenchymal' named entity 'NYU' named entity 'Tisch Hospital' named entity 'intensive care units' named entity 'long-term' named entity 'hemorrhage' named entity 'Argatroban' named entity 'hemorrhage' named entity 'UFH' named entity 'enoxaparin' named entity 'MRI' named entity 'hemorrhages' named entity 'subcutaneously' named entity 'antiplatelet therapy' named entity 'venous thromboembolism' named entity 'eGFR' named entity 'COVID' named entity 'informed consent' named entity 'neuroimaging' named entity 'thrombosis' named entity 'D-dimer' named entity 'radiographic' named entity 'expert opinion' named entity 'anticoagulation' named entity 'Acute Stroke' named entity 'Institutional Review Board' named entity 'antiplatelet therapy' named entity 'hemorrhage' named entity 'subcutaneously' named entity 'COVID' named entity 'mass effect' named entity 'mass effect' named entity 'D-dimer' named entity 'neuroimaging' named entity 'UFH' named entity 'COVID-19' named entity 'HIT' named entity 'heparin-induced thrombocytopenia' named entity 'thrombus' named entity 'anticoagulation' named entity 'hemorrhage' named entity 'sample size' named entity 'ischemic stroke' named entity 'COVID-19' named entity 'parenchymal' named entity 'hemorrhages'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software